Prolymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Prolymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-06-19Clinical Trial Update: AZD6738 First Time in Patient Multiple Ascending Dose Study [Phase 1]
AZD6738 (berzosertib) was studied in a first-in-patient, multiple ascending-dose Phase 1 trial in relapsed/refractory hematologic cancers in…
-
CLINICAL_TRIALS trial_result · 2014-01-09Clinical Trial Update: Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia [NA]
This clinical trial update reports compassionate-use treatment with Campath-1H (alemtuzumab) for patients with refractory prolymphocytic leu…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial update of obatoclax, fludarabine, and rituximab in previously treated chronic lymphocytic leukemia; the study was terminated.
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia [Phase 1]
A Phase 1 trial of tanespimycin (17-N-allylamino-17-demethoxygeldanamycin) with or without rituximab in relapsed B-cell chronic lymphocytic …
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]
A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-08-29Clinical Trial Update: Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL [Phase 1, Phase 2]
A Phase 1/2 study evaluating oxaliplatin, fludarabine, cytarabine, and rituximab in Richter's syndrome and refractory chronic lymphocytic le…
-
CLINICAL_TRIALS trial_result · 2010-06-22Clinical Trial Update: BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of BL22 immunotoxin in patients with refractory chronic lymphocytic leukemia, prolymphocytic leukemia, and non-Hodgkin lymphom…